Results 191 to 200 of about 72,525 (247)

Direct measurement of in vivo BCR::ABL1 kinase inhibition reveals stronger potency of asciminib as compared with imatinib and nilotinib. [PDF]

Leukemia
Kok CH, Shanmuganathan N, Saunders VA, Dang P, White D, Branford S, Yeung D, Hughes TP.   +7 more
europepmc   +1 more source

Repurposing primaquine diphosphate for imatinib-resistant chronic myeloid leukemia via targeting BCR-ABL and Wnt/β-catenin pathway. [PDF]

iScience
Yin C, Liu W, Ma C, Zhang Z, Fang Z, Cao J, Wu G, Gu H, He L.   +8 more
europepmc   +1 more source

Chronic Eosinophilic Leukemia Not Otherwise Specified: A Case Series. [PDF]

J Hematol
Varada NL, Dougherty Bordes K, Redemann JP, Ebaid A.   +3 more
europepmc   +1 more source

Matching-adjusted indirect comparison between asciminib and flumatinib as first-line treatment for chronic myeloid leukemia in China. [PDF]

Transl Cancer Res
Wang Y, Hui Y, Zhang L, Li Y, Tang M, Gao X, Zhen B, Choubey A, Gupta S, Wei H, Liu B.   +10 more
europepmc   +1 more source

Design, Synthesis and Biological Evaluation of Novel Oleanolic Acid Derivatives as Potential Anti-Leukemic Agents. [PDF]

Life (Basel)
Demir N, Ciftci H, Elamin KM, Can M, Sever B.   +4 more
europepmc   +1 more source

Discovery of a Novel 4,5-Dihydro-1<i>H</i>-pyrazole-1-carbothioamide Derivative with Cytotoxic, Apoptotic, and ABL1 Inhibitory Activities Against Chronic Myeloid Leukemia. [PDF]

Biomedicines
Erkan A, Irgit Calayir A, Ciftci H, Sever B.   +3 more
europepmc   +1 more source

Longitudinal analysis of tyrosine kinase inhibitor therapy outcomes and BCR-ABL1 transcript decline velocity in chronic myeloid leukemia: A 16-year real-world study. [PDF]

Cancer
Mustafa Ali MK, Zabor EC, Abdurakhmanov K, Zureigat H, Mohamed AN, Alchirazi MA, Dhakal A, Mushtaq A, Rehman N, Bawwab A, Berube B, Khatib L, Jain AG, Molina JC, Balderman S, Singh A, Gerds AT, Sobecks R, Advani AS, Carraway HE, Kalaycio M, Mukherjee S.   +21 more
europepmc   +1 more source

Complementary efficacy of CD127-directed immunotherapy with lusvertikimab and ABL-targeting tyrosine kinase inhibitors in preclinical ABL-class-fusion-positive B-ALL. [PDF]

Hemasphere
Pinkle D, Cornils M, Dietterle A, Laqua A, Kurschies M, Heymann J, Funke E, Fanter P, Gupta DD, Reimer C, Mahachi DT, Gehlert CL, Winterberg D, Vossen-Gajcy M, Müller X, Balow G, Iben K, Barz M, Bastian L, Baldus C, Kowol M, Kikvadze S, Wurm AA, Logvinova E, Vokuhl C, Schmid JP, Jeremias I, Klausz K, Peipp M, Schrappe M, Baccelli I, Poirier N, Brüggemann M, Cario G, Schewe DM, Lenk L.   +35 more
europepmc   +1 more source

Interleukin-6 is a mediator of therapeutic efficacy in acute lung injury. [PDF]

Am J Respir Crit Care Med
Kramer L, Calfee CS, McAuley DF, O'Kane C, Aman J, Duijvelaar E, Giamarellos-Bourboulis EJ, Antonakos N, Heymans MW, Bos LDJ.   +9 more
europepmc   +1 more source